Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions-Reference-Cited by-同舟云学术

Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions

Published:2010-05 Issue:7-8 Volume:43 Page:666-670
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Riondino Silvia,Martini Francesca,La Farina Francesca,Spila Antonella,Guadagni Fiorella,Ferroni Patrizia

Publisher

Elsevier BV

Subject

Clinical Biochemistry,General Medicine

Reference40 articles.

1. Membrane-associated CD40L and sCD40L in atherothrombotic disease;Anand;Thromb. Haemost.,2003

2. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes;Paulie;Cancer Immunol. Immunother.,1985

3. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50;Clark;Proc. Natl. Acad. Sci. U.S.A.,1986

4. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells;Noelle;Proc. Natl. Acad. Sci. U.S.A.,1992

5. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation;Yellin;J. Leukoc. Biol.,1995

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Release of α-granule contents during platelet activation;Platelets;2021-09-25

2. Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease;Frontiers in Cardiovascular Medicine;2021-06-21

3. Prospective Determination of Aspirin Sensitivity in Patients Resistant to Low Dose Aspirin: A Proof of Concept Study;The Journal of Clinical Pharmacology;2018-05-18

4. Platelet sequestration with a new-generation autotransfusion device;Transfusion;2018-01-30

5. Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients;Oncotarget;2016-08-05